Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC

Opinion
Video

Arvind N. Dasari, MD, MS, gives an overview of the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA clinical trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected
      Recent Videos
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      CRS Recognition and Intervention: Timing and Clinical Features
      CRS Recognition and Intervention: Timing and Clinical Features
      Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
      Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
      Related Content
      Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

      Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

      Tim Cortese
      June 17th 2025
      Article

      A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

      Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

      Roman Fabbricatore
      June 11th 2025
      Article

      Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

      Jagoda Misniakiewicz, PharmD
      June 10th 2024
      Podcast

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

      Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo

      Russ Conroy
      May 31st 2025
      Article

      Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

      Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

      Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

      Jordyn Sava
      May 31st 2025
      Article

      The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.